

PTO/SB/08A

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)



| | | | | Complete if Known | |
|-------|---|----|---|--------------------------|------------------------|
| | | | | Application Number | 09/843,132 |
| | | | | Filing Date | April 25, 2001 |
| | | | | Confirmation Number | 8349 |
| | | | | First Named Inventor | John P. McKearn et al. |
| | | | | Group Art Unit | 1614 |
| | | | | Examiner Name | Rebecca Cook |
| Sheet | 1 | of | 2 | Attorney Docket No. | PHA 2004 (3167/12/US) |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY |
|--------------------|-----------------------|----------------------|--------------------------------------|---|---|
| | | Number | Kind Code ² (if known) | | |
| h | 44. | 6,077,850 | | Carter et al. | 06-20-2000 |
| h | 45. | 6,087,392 | | Reiter | 07-11-2000 |
| h | 46. | 6,110,964 | | Robinson | 08-29-2000 |
| h | 47. | 6,114,361 | | Robinson et al. | 09-05-2000 |
| h | 48. | 6,156,798 | | Reiter | 12-05-2000 |
| h | 49. | 6,214,870 | B1 | McClure et al. | 04-10-2001 |
| h | 50. | 6,277,878 | B1 | Nakao et al. | 08-21-2001 |
| h | 51. | 6,294,558 | B1 | Ando et al. | 09-25-2001 |
| h | 52. | 6,303,628 | B1 | Nakao et al. | 10-16-2001 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | T ⁶ |
|--------------------|-----------------------|-------------------------|---------------------|--------------------------------------|---|---|----------------|
| | | Office | Number ⁴ | Kind Code ² (if known) | | | |
| h | 53. | EP | 1 081 137 | A1 | Pfizer Products Inc. | 03-07-2001 | |
| h | 54. | EP | 1 088 550 | A1 | Pfizer Products Inc. | 04-04-2001 | |

| | | | |
|--------------------|-------------|-----------------|----------------|
| Examiner Signature | <i>Mook</i> | Date Considered | <i>7/10/04</i> |
|--------------------|-------------|-----------------|----------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A

**SUPPLEMENTAL
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

**Complete if Known**

| | | | | | |
|----------------------|------------------------|----|---|---------------------|-----------------------|
| Application Number | 09/843,132 | | | | |
| Filing Date | April 25, 2001 | | | | |
| Confirmation Number | 8349 | | | | |
| First Named Inventor | John P. McKearn et al. | | | | |
| Group Art Unit | 1614 | | | | |
| Examiner Name | Rebecca Cook | | | | |
| Sheet | 2 | of | 2 | Attorney Docket No. | PHA 2004 (3167/12/US) |

| | | | | | | | |
|---|-----|----|-----------|----|-------------------------------|------------|--|
| N | 55. | EP | 1 104 759 | A1 | Pfizer Products Inc. | 06-06-2001 | |
| ✓ | 56. | EP | 1 104 760 | A1 | Pfizer Products Inc. | 06-06-2001 | |
| ✓ | 57. | EP | 1 134 215 | A1 | Pfizer Products Inc. | 09-19-2001 | |
| N | 58. | EP | 1 138 680 | A1 | Pfizer Products Inc. | 10-04-2001 | |
| ✓ | 59. | WO | 97/20824 | A1 | Agouron Pharmaceuticals, Inc. | 06-12-1997 | |
| ✓ | 60. | WO | 98/03516 | A1 | Pfizer Inc. | 01-29-1998 | |
| ✓ | 61. | WO | 98/30566 | A1 | Pfizer Inc. | 07-16-1998 | |
| ✓ | 62. | WO | 98/47890 | A1 | G.D. Searle & Co. | 10-29-1998 | |
| ✓ | 63. | WO | 99/21583 | A1 | Warner-Lambert Company | 05-06-1999 | |
| ✓ | 64. | WO | 00/09485 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| ✓ | 65. | WO | 00/09492 | A1 | Pfizer Products Inc. | 02-24-2000 | |
| ✓ | 66. | WO | 00/73294 | A2 | Pfizer Products Inc. | 12-07-2000 | |
| ✓ | 67. | WO | 01/12611 | A1 | Pfizer Products Inc. | 02-22-2001 | |
| ✓ | 68. | WO | 01/40216 | A1 | Pfizer Products Inc. | 06-07-2001 | |

OTHER ART - NON PATENT LITERATURE DOCUMENTS

| | | | |
|--------------------|-----------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ⁶ |
| ✓ | 69. | TRIFAN, O.C., et al., Cyclooxygenase-2 Inhibition with Celecoxib Enhances Antitumor Efficacy and Reduces Diarrhea Side Effect of CPT-11, Cancer Research, Oct. 15, 2002, pp. 5778-84, Vol. 62, No. 20 | |

| | | | |
|--------------------|---------------------|-----------------|---------|
| Examiner Signature | <i>Rebecca Cook</i> | Date Considered | 7/10/04 |
|--------------------|---------------------|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.